The effect of medrogestone on plasma lipids and lipoproteins in postmenopausal women using conjugated estrogens : an open randomized comparative study by Gevers Leuven, J.A. et al.






The following full text is a publisher's version.
 
 





Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
F e r t il i t y  a n d  S t e r i l i t y
Copyright  ^ 1995 American Society for Reproductive Medicine
Vol. 64, No. 3, September 1995 
Printed on acid-free paper in U. S. A,
The effect of medrogestone on plasma lipids and lipoproteins in 
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O bjective: To test the hypothesis that the progestogen medrogestone has no effect on changes 
in lipoprotein metabolism evoked by continuous estrogen replacement therapy, paying special 
attention to high-density lipoproteins (HDL).
D esign : Open multi center randomized comparative trial.
P a tien ts: Postmenopausal hysterectomized women aged 49 to 64 years.
In terven tion : Continuous oral treatm ent with 0.625 m g d a ily o f conjugated estrogens (CE) 
alone (n = 55) or CE plus 5 mg of the progestogen medrogestone orally during the last 12 days 
of each 28-day cycle (n = 59).
M ain O utcom e M easures: At baseline and at cycles 3 ,6 , and 13 we measured the plasma 
levels of apolipoprotein (Apo) Al, cholesterol in  total HDL and in its subfractions HDL2 and 
HDL3, using density gradient ultracentrifugation.
R esu lts: High-density lipoprotein cholesterol increased from baseline at all assessments in 
both treatment groups, being significantly greater in the CE group (+15% a t cycle 13) th an  in 
the CE and medrogestone group (+8%). However, HDL2-cholesterol increased in both treatm ent 
groups, but with no significant difference between the two groups. High-density lipoprotein 3 
cholesterol increased only in the CE group (+7% at cycle 13); there was no significant change in 
HDL3-cholesterol in the CE and medrogestone group. Low-density lipoprotein (LDL) cholesterol 
decreased from baseline at all assessments in both treatm ent groups (—6% and —9%, respec­
tively, at cycle 13). The change in very low-density (VLDL) lipoprotein cholesterol was not 
significant in either of the two groups. Medrogestone had no significant effects on the estrogen- 
induced increases in apo A-l and triglycerides nor on the decreases in ApoB and LDL-cholesterol. 
Neither hormone significantly affected VLDL-cholesterol or Lp(a) levels.
C onclusion: Medrogestone did not eliminate the increase in plasma HDL levels evoked by 
CE. Fertil Steril 1995;64:525-31
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Postmenopausal estrogen replacement therapy is 
associated with a 50% reduction in the incidence of 
myocardial infarction (1). Although selection, bias (2) 
and direct effects on the vessel wall and other mech­
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anisms (3) may explain part of this apparent effect, 
it is plausible that the concomitant changes in lipo­
protein metabolism contribute to the mechanism of 
protection. In postmenopausal women the plasma 
level of the atherogenic low-density lipoproteins 
(LDL) increases (4) and that of the antiatherogenic 
high density lipoproteins (HDL) decreases (4). Oral 
estrogen replacement reverses these changes (5). 
The addition of a progestogen to estrogen therapy 
currently is recommended to prevent endometrial 
adenocarcinoma. Progestogens have not been shown 
to have an untoward effect on the prevalence of isch­
emic heart disease, although they generally attenu­
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ate the estrogen-induced increase in plasma HDL- 
cholesterol levels (6). This effect is more marked 
with nortestosterone-derived progestogens than 
with those derived from 17-liydroxy-progesterone 
(5), such as medrogestone (7-9).
Previous studies of the effect of medrogestone on 
lipoprotein levels in postmenopausal women treated 
with conjugated estrogens had various weaknesses: 
they either were uncontrolled (8), included small 
numbers of patients (7-9), or only six cycles were 
analyzed (7). We studied hysterectomized postmeno­
pausal women during 1 year of treatment in an open 
randomized comparative multicenter trial using 
semiautomated density gradient ultracentrifugation 
to estimate the changes in lipoprotein subfractions.
MATERIALS AND METHODS
Postmenopausal women were recruited by adver­
tisement and articles in daily newspapers. Women 
aged 50 to 65 years who had undergone hysterec­
tomy were eligible for enrollment if they had serum 
FSH levels >40 mlU/mL (conversion factor to SI 
unit, 1.00) and serum E2 levels <40 pg/mL (conver­
sion factor to SI unit, 3.67).
Those who had taken estrogens and/or progesto­
gens orally <3 months before prestudy screening or 
had hypersensitivity to estrogens and/or progesto­
gens were excluded. Smoking >15 cigarettes per day 
and known alcohol abuse also excluded a subject 
from participating. In addition, the subjects could 
not weigh >20% of their ideal weight or have blood 
pressure (sitting) >160 mm Hg systolic or >90 mm 
Hg diastolic, serum cholesterol >6.72 mmol/L (con­
version factor, 38.7), or serum triglycerides >2.84 
mmol/L (conversion factor, 88.0). Other exclusion 
criteria were a Papanicolaou smear of class III or 
more; thrombophlebitis; thromboembolic disorders 
related to estrogen therapy; ischemic heart disease; 
chronic liver, renal, cerebral, or gallbladder disease; 
malabsorption; evidence of estrogen-dependent neo­
plasia; and endocrine disease, except for controlled 
thyroid disease.
Written informed consent was obtained before 
study entry. The study was approved by the Commit­
tee of Medical Ethics of all five centers.
Two groups were formed by randomization using 
a computer program. Fifty-six women used 0.625 mg 
of conjugated estrogens (CE; Premarin; Wyeth Labo­
ratories, Hoofddorp, The Netherlands) continuously; 
60 women took the same dosage of CE continuously 
plus 5 mg medrogestone (6,17-dimethylpregna-4,6- 
diene-3,20-dione, Colprone; Wyeth Laboratories) 
added the last 12 days of each 28-day cycle (CE and 
medrogestone)*
Blood samples were obtained in the morning, after
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an overnight fast (12 to 14 hours). They were centri­
fuged at 3,000 rpm for 15 minutes at 4°C to obtain 
serum or plasma. Serum (from Nijmegen only) was 
ultracentrifuged immediately but the plasma sam­
ples were snap-frozen in liquid nitrogen and stored 
at -70°C until ultracentrifugation within 6 months. 
Spare samples were kept at —20°C for measurement 
of the apolipoprotein level within 18 months.
Two baseline blood samples were taken with >1 
week in between. During the study, blood samples 
were drawn between the 22nd and 28th day of the 
3rd, 6th, and 13th cycles. Physical examination, rou­
tine hematologic and blood chemistry tests, and a 
urinalysis were performed at baseline and at the end 
of the study.
Serum FSH and E 2 levels were determined using 
commercial kits at each site; determinations of lipids 
for screening and for scientific endpoints were per­
formed using enzymatic methods (CHOD-PAP cho­
lesterol reagent and GPO-PAP triglyceride reagent; 
Boehringer Mannheim, Mannheim, Germany).
The lipoprotein profile was determined in 2 mL 
serum or plasma, after quick-thawing at 37°C. Den­
sity gradient ultracentrifugation was performed (10) 
without previous staining using a 12-mL polypropyl­
ene tube in a SW40 Ti. rotor for 18 hours at 40,000 
rpm at 4°C in a Beckman L7-55 ultracentrifuge 
(Beckman Instruments, Palo Alto, CA). The top 1.5 
mL from the tube was removed by gentle suction 
with a pipette and stored for further determinations 
(cholesterol and triglycerides). Further fractionation 
was performed by using a capillary placed on the 
bottom of the tube, attached to a micropump and a 
fraction collector, producing fractions of 250 fiL each. 
All fractions were weighed (Mettler PM-2000; Met- 
tler-Toledo, Greifensee, Switzerland); the density 
was determined using a density-measuring cell 
DMA 602 M (Mettler/Paar, Graz, Austria). Both the 
scale and the densitometer were linked to a personal 
computer to calculate the volume of each fraction 
with three decimal places. A Gilson 222 (Gilson Med­
ical Electronics S.A., Villiers-le-Bel, France) sample 
changer and a Dilutor 401 (Gilson Medical Electron­
ics S.A.) were used for routine purposes. The area 
under the curve (AUC) comprising the fractions with 
a density between 1.21 and 1.125 g/mL was used to 
estimate HDL3-cholesterol; HDL2-cholesterol and 
LDL-cholesterol were estimated by using the AUC 
between 1.125 and 1.085 g/mL and the AUC between 
1.085 and 1.019 g/mL, respectively. Apolipoproteins 
(Apo) A-l and B, and lipoprotein (Lp) (a) were deter­
mined in random fashion by rate immunonephe- 
lometry using a Beckman Array Protein system 
(Beckman Instruments) (11).
A sample size of 50 women in each treatment 










Age (y) 54.9 ± 3.9 55.3 ± 3.8 0.53
(49 to 64) (49 to 64)
Height (cm) 165 ± 6.3 164 ± 5.0 0.34
(153 to 178) (156 to 178)
Weight (kg) 69.1 ± 7.4 67.3 ±7 . 1 0.19
* (54 to 86.5) (50 to 81)
Quetelet index-t 25.4 ± 2.8 25.0 ± 2.5 0.54
(20.2 to 32.7) (18.4 to 30.8)
Values are means ± SD with ranges in parentheses, 
t Difference between the two groups.
$ Quetelet index -  (weight in kg)/(height in m)2.
in the key lipid parameters of 0.40 mmol/L in total 
cholesterol; 0.25 mmol/L in triglyceride; 0.20 mmol/ 
L in HDL cholesterol and 0.38 mmol/L in LDL cho­
lesterol with a power of 80% at a level of significance 
of 0.05 (two-tailed test). The adequacy of the ran­
domization was assessed by comparing the two 
treatment groups at baseline using the Student’s £- 
test or Mann-Whitney U-test. The primary efficacy 
variables were the percentage change from baseline 
in HDL, total cholesterol, triglycerides, and LDL. An 
intent-to-treat analysis was performed for all pa­
tients assigned to treatment who received at least 
one dose of medication and had at least one efficacy 
evaluation during therapy.
Analysis of covariance (ANCOVA) was performed 
on the lipid parameters at each scheduled observa­
tion with the baseline value as a covariate and treat­
ment, center, and treatment by center interaction as 
factors. The assumptions of normality were broken 
for HDL, triglycerides, and very low-density lipopro­
tein (VLDL), and these parameters were analyzed 
with the Mann Whitney [/‘-test. Comparisons within 
treatment groups were made using the paired ¿-test 
or Wilcoxon matched pairs signed ranks test.
The x2 test was used for comparisons between 
groups of the proportion of patients who discon­
tinued treatment, both overall and for specific rea­
sons. Vital signs and laboratory data were analyzed 
by ANCOVA with the baseline value as a covariate 
and treatment, center, and treatment by center in­
teractions as factors.
RESULTS
A total of 116 postmenopausal women were en­
rolled in this trial; none of them took any drugs af­
fecting lipid metabolism. Fifty-six were assigned 
randomly to receive CE alone and 60 were assigned 
to receive CE and medrogestone. Tables 1 and 2 
show the clinical characteristics at baseline. Except
for VLDL cholesterol, the two groups did not show 
any statistically significant difference at baseline 
(Tables 1 and 2). Two patients, one from each treat­
ment group, were excluded because of high 17-/?-E2 
at baseline, leaving 55 in the CE group and 59 in 
the CE and medrogestone group. Thus, 114 patients 
commenced treatment. Eight women from the CE 
group and 14 from the CE and medrogestone group 
withdrew. The primary reasons for withdrawal in 
the CE group were nausea (n = 1); asthenia, depres­
sion, and dizziness (n = 1); mastodynia (n = 1); ankle 
edema (n = 1); and hemangioma in the liver (n = 1). 
In the CE and medrogestone group the primary rea­
sons for withdrawal were vertigo (n = 1); exacerba­
tion of depression (n -  1); headache (n = 3); weight 
gain and dysuria (n = 1); weight gain and itching (n 
= 1); mastodynia (n = 1); and thrombophlebitis (n 
= 1). One patient withdrew because of a non-medical 
event in the CE group. In the CE and medrogestone 
group three patients withdrew because of medical 
reasons not attributed to the medication, i.e., hy­
drops in knee (n = 1); infection in thumb (n = 1); 
and cholelithiasis (n = 1). Furthermore, in this group 
one patient failed to return and one patient re­
quested to withdraw because of nonmedical reasons. 
Fifty-two patients in the CE group and 51 in the 
CE and medrogestone group had at least one on- 
treatment lipid assessment. The full 13 cycles of the 
study were completed by 47 and 41 patients, respec-
Table 2 Concentration of Lipids, Lipoprotein-lipids, and 
Apolipoproteins at Baseline in Serum or Plasma*
CE 
(n = 55)
CE and  
medrogestone 




(Conversion factor to 
conventional units, 38.7) 5.78 ±  0.70 5.94 ± 0.73 0.22
LDL cholesterol 
(Conversion factor to 
conventional units, 38.7) 3.77 ±  0.G1 3.80 ± 0.69 0.78
VLDL cholesterol 
(Conversion factor to 
conventional units, 38.7) 0.53 ± 0,49 0.67 ± 0.28 0.01
Total triglycerides 
(Conversion factor to 
conventional units, 88.0) 1.17 ± 0.51 1.35 ± 0.58 0.07
Apolipoprotein B (mg/dL) 1.26 ± 0.23 1.31 ± 0.27 0.29
HDL cholesterol 
(Conversion factor to 
conventional units, 38.7) 1.47 ± 0.32 1.47 ± 0.28 0.98
HDL2 cholesterol 
(Conversion factor to 
conventional units, 38.7) 0.41 ± 0.17 0.40 ± 0.19 0.76
HDL3 cholesterol 
(Conversion factor to 
conventional units, 38.7) 0.99 ± 0.20 0.99 ± 0.16 0.85
Apolipoprotein A -l (mg/dL) 1.61 ± 0.24 1.61 ±  0.19 0.98
Lipoprotein (a) (mg/dL):j: 15 (4.4 to 38) 10 (3.7 to 25) 0.38
Values are m eans ±  SD. 
t  Difference between the two groups.
$ Values a re  m edians with in te rquartile  range in  parentheses; n = 45 
for CE group; n  = 41 for CE and  medrogestone group.
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Figure 1 Typical pattern of 
the cholesterol concentration 
as a function of the density 
after gradient ultracentrifu­
gation for a patient from the 
CE and medrogestone group 
before (O) and after (•) three 
cycles. The AUC between 
1.21 and 1.125 g/mLhas been 
defined as HDL3-cholesterol, 
between 1.125 and 1,085 g/ 
mL as HDL2-cholesterol, and 
between 1.085 and 1.019 g/ 
mL as LDL.
tively, including four patients of the CE and me­
drogestone group who had no lipid assessment at 
cycle 13.
Body weight did not change significantly through­
out the study, and no therapy difference could be 
discerned. Also, no differences were found in labora­
tory values such as hematocrit, hemoglobin, platelet 
count, white cell count, albumin, alkaline phospha­
tase, calcium, chloride, creatinine, glucose, phospho­
rus, total bilirubin, potassium, sodium, total protein, 
and uric acid.
Supine blood pressure at baseline (mean ± SD) in 
the CE group was 132 ± 17 mm Hg systolic and 81 
± 7.5 mm Hg diastolic and in the CE and medroge­
stone group was 132 ± 11.5 mm Hg systolic and 
82 ± 6.2 mm Hg diastolic. During therapy a slight 
lowering by 5% at cycle 6 and by 4% at cycle 9 was 
found in the CE and medrogestone group only (both 
P < 0.05), but this apparent effect faded thereafter. 
No difference in change between the two groups was 
found in this respect.
Figure 1 shows a typical ultracentrifugation pat­
tern before and after three cycles of therapy with 
CE and medrogestone. Very low-density-lipoprotein 
cholesterol is omitted in this figure because it had 
been removed before fractionation.
Table 3 shows the percentage changes in the 
plasma lipid, lipoprotein lipid, and apolipoprotein 
levels. High-density-lipoprotein cholesterol in­
creased significantly from baseline at all assess­
ments in both treatment groups. At cycle 3 and at
cycle 13 of therapy, the HDL-cholesterol levels in­
creased significantly more in the CE group than in 
the CE and medrogestone group (difference in 
change P < 0.001 at cycle 3 only), High-density-lipo- 
protein-2 cholesterol increased significantly from 
baseline at all assessments in both treatment 
groups, but between the two groups the difference 
in the change of HDL2-cholesterol was not signifi­
cant. The HDL3-cholesterol levels increased signifi­
cantly from baseline at all assessments in the CE 
group but not in the CE and medrogestone group. 
The CE group showed a significantly greater in­
crease than in the CE and medrogestone group at 
cycle 3 only (P = 0.011). Similar highly significant 
increases in the Apo A-l levels were seen in both 
groups and were not affected by the smaller number 
of subjects at the end of the study.
The total plasma cholesterol level decreased .sig­
nificantly more in the CE and medrogestone group 
than in the CE group at cycles 3 and 6. Plasma tri­
glyceride levels increased significantly and to a simi­
lar extent in both treatment groups. Because triglyc­
eride levels reflect the VLDL concentration, this 
variable correlated with VLDL cholesterol (not 
shown). Lipoprotein (a) did not differ from baseline 
at cycle 13 of therapy in either of the two groups and 
showed no correlation with any of the other variables.
DISCUSSION
The main purpose of this study was to investigate 
the effect of medrogestone on the estrogen-induced
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Table 3 Percentage Change in Plasma Lipid and Lipoprotein Levels From Baseline*
CE CE and medrogestone P
No. of patients
Cycle 3 52 51
Cycle 6 49 48
Cycle 13 47 41
Total cholesterol*
Cycle 3 -0.89 ± 1.37 -6.45 ± 1.39$ 0.008
Cycle 6 0.77 ± 1.62 -5.32 ± 1.60$ 0.016
Cycle 13 1.46 ± 1.41 -3.76 ± 1.6611 0.077
LDL cholesterol*
Cycle 3 -9.49 ± 1.80$ -11.77 ± 1.74$ 0.25
Cycle 6 -7.59 ± 1.90t -12.38 ± 2.08$ 0.12
Cycle 13 -5.89 ± 1.65$ -9.07 ± 2.28$ 0.33
VLDL cholesterolf
Cycle 3 13.19 (-25.32; 43.48) -9.43 (-35.53; 44.68) 0.22
Cycle 6 6.52 (-14.06; 62.50) 3.79 (-25.97; 45.03) 0.44
Cycle 13 8.16 (—17.57; 48.08) 10.75 (-26.98; 41.67) 0.61
HDL cholesterolf
Cycle 3 16.17 (8.28; 25.87)$ 8.15 (-2.97; 16.13)$ <0.001
Cycle 6 15.71 (6.25; 22.90)$ 8.88 (-0.93; 21.17)$ 0.066
Cycle 13 14.67 (5.00; 26.99)$ 7,63 (-0.87; 21.05)$ 0.032
HDL2 cholesterolf
Cycle 3 40.19(14.16; 94.29)$ 27.27 (5.40; 62.86)$ 0.14
Cycle 6 44.44 (17.14; 75.76)$ 33.77 (-1.35; 60.24)$ 0.18
Cycle 13 45.16 (21.21; 78.57)$ 30.30 (0,00; 55.00)$ 0.071
HDL3 cholesterol!
Cycle 3 6.49 (-2.07; 21.55)$ -1.55 (10.20; 9.09) 0.011
Cycle 6 6.54 (-6.25; 14.29)|| 2.88 (-7.32; 11,37) 0.343
Cycle 13 7.14 (-3.50; 19.75)|j 1.02 (-6,54; 10.09) 0,227
Triglycerides!
Cycle 3 12.44 (-9.09; 36.40)|| 8.55 (-13.48; 42.42)|| 0.67
Cycle 6 19.30 (-8.46; 55.91)$ 19.69 (-5.25; 44.62)$ 0.73
Cycle 13 16.46 (-6,54; 40.72)§ 19.07 (-6.06; 50.00)$ 0.75
Apo A-P
Cycle 3 15.3 ± 1.4$ 11.6 ± 1.6$ 0.18
Cycle 6 16.0 ± 1.6$ 12.5 ± 1.5$ 0.054
Cycle 13 16.1 ± 2.0$ 13,6 ± 1.5$ 0.048
Apo B*
Cycle 3 -3 .3  ± 1.7 -4 .9  ± l.S§ 0.61
Cycle 6 -0 .2  ± 2.4 -4 .9  ± 2.011 0.063
Cycle 13 1.8 ± 1,5 -1 .7  ± 2.0 0,025
Lp(a)f
Cycle 13 -1 .9  (-28.3; 13.1) -9 .2  (-38,1; 14.5) 0.46
* Values are means ± SEM.
t Values are medians with interquartile ranges in parentheses. 
$ Change from baseline significantly different from zero, P 
< 0.001.
§ Change from baseline significantly different from zero, P 
< 0.01.
|| Change from baseline significantly different from zero, P 
<0.05.
rise in plasma levels of HDL cholesterol and those of 
other lipoproteins. Several lines of evidence suggest 
that HDL inhibits atherogenesis directly or indi­
rectly or even enhances the regression of plaques: 
HDL is involved in cholesterol reverse transport 
(12); given IV, HDL inhibits plaque formation in cho­
lesterol-fed rabbits (12); transgenic mice containing 
multiple copies of Apo A-l develop less fatty streaks 
than mice without the extra genes (13); and primary 
Apo A-l deficiency in human subjects is associated 
with early ischemic heart disease (14). The plasma 
level of HDL cholesterol is the sum of the cholesterol 
content of two subfractions, the less-dense HDL2 
and the denser HDL3. Generally the former is more 
variable (15) and more sensitive to sex steroids (6)
than the latter. This subfractionation does not pro­
vide more information on cardiovascular risk than 
the total HDL cholesterol level (15, 16). However, 
to gain more insight into the possible mechanisms 
behind the changes, subfractionation of HDL can be 
worthwhile. The hepatic triglyceride lipase activity 
is involved in the conversion of HDL2 into HDL3, 
and this enzyme is inhibited by estrogens (17). That 
would explain the increase in HDL2 but not that in 
HDL3. On the other hand, androgenic side effects 
of a progestogen may enhance hepatic triglyceride 
lipase activity (6, 17). Thus, if medrogestone would 
have had any androgenicity it probably would have 
become visible as a prevention of the increase of 
HDL2 in the CE and medrogestone group. In fact
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the rise in HDL2 was not significantly smaller in 
the CE and medrogestone group than in the CE 
group. Thus, the inhibition of hepatic triglyceride 
lipase activity by estrogens in the presence of me­
drogestone may have been similar to that in the CE 
group. The HDL3 subfraction showed a greater in­
crease in the CE group than in the CE and medroge­
stone group, suggesting that other factors besides 
hepatic triglyceride lipase activity were effective, 
e.g., a difference in the estrogen-induced Apo A-l 
synthesis rate (18). In later cycles this difference 
in change diminished. Fahreus and Wallentin (19), 
using sequential ultracentrifugation for the estima­
tion of HDL2 and HDL3, also found an increase in 
HDL3 level, but only with the high dosage of 4 mg 
of oral micronized 17-/?-E2. Two other factors in­
volved in HDL cholesterol levels are known, i.e., leci­
thin: cholesterol acyltransferase, which adds cholest- 
erolester to the payload of HDL, causing transition 
from HDL3 to HDL2. Cholesterolester transfer pro­
tein transfers cholesterol ester from HDL to triglyc- 
eride-rich lipoproteins like VLDL in exchange for 
triglycerides, causing a decrease in HDL2. However, 
neither of these two factors has been reported to be 
affected by sex steroids.
Our results partly confirm those of Sonnendecker 
et al. (7), who performed a randomized, placebo con­
trolled, double-blind crossover study with 22 partici­
pants for six cycles. They found no additional effect 
on HDL subfractions of cyclic 5 mg medrogestone 
plus 0.625 mg CE when compared with 0.625 mg CE 
alone, whereas we did. However, this group used a 
precipitation technique to separate HDL2 from 
HDL3. Teichmann et al. (8) performed an uncon­
trolled study of the effect of 5 mg medrogestone plus 
1.25 mg CE on lipoprotein lipids and apolipoproteins 
in 20 oophorectomized patients during 12 cycles. 
They used a quantitative electrophoretic method to 
estimate lipoproteins, which did not allow for esti­
mation of HDL subfractions.
Plasma total cholesterol level decreased in both 
groups and significantly more in the CE and me­
drogestone group than in the CE group in the first 
three cycles, whereas the decrease in LDL was not 
significantly different in the two groups. Obviously 
the explanation for this discrepancy should be that 
total cholesterol, being the sum of cholesterol all dif­
ferent classes of lipoproteins, reflects the change in 
all these classes. Beyond any doubt, changes in LDL 
cholesterol levels and Apo B levels can be interpreted 
in terms of cardiovascular risk. The similar decrease 
in the average LDL cholesterol level and in the Apo 
B level in both treatment groups therefore is reas­
suring. The clearance of LDL is mainly receptor de­
pendent, and the LDL receptor activity is enhanced 
by oral estrogen treatment (20). Apparently in this
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study, 5 mg of medrogestone in a cyclic regimen did 
not attenuate this estrogen effect on the LDL recep­
tors to an extent sufficient to interfere with the low­
ering of the plasma LDL levels by estrogens. If me­
drogestone exerted any androgenic effect in the liver, 
lower VLDL production (21) and, consequently, de­
creased LDL synthesis and lower plasma LDL levels 
would have resulted. However, that has not been 
found. In fact, fasting plasma triglyceride levels, 
which reflect the VLDL concentration and VLDL 
production, were not significantly different between 
the two groups throughout the treatment period. Fi­
nally, the LDL production rate might have been low­
ered by an increased clearance of VLDL remnants 
just before their conversion into LDL. This explana­
tion is given for the observation in female patients 
with Familial Dysbetalipoproteinemia, in whom ac­
cumulated VLDL remnants in plasma can be low­
ered by oral estrogen therapy (22).
The Lp(a) levels did not differ significantly from 
baseline at cycle 13. This is in contrast to the obser­
vational study of Nabulsi et al. (23) who found 13% 
lower Lp(a) levels among current estrogen users 
than among nonusers and with a persistent decrease 
of Lp(a) from baseline during another study of hor­
mone replacement therapy (24). It should be remem­
bered that the effect of sex steroids on Lp(a) may 
be transient (25) and that we may have missed an 
eventual decrease in Lp(a). We found no significant 
correlation between Lp(a) and either LDL choles­
terol or Apo B.
We conclude that medrogestone given in the dose 
regimen of this study has little effect on estrogen- 
induced changes in lipoprotein metabolism and that 
in these terms no objection can be made against the 
use of this 17-hydroxyprogesterone-derived proges­
togen for adjunct treatment in postmenopausal hor­
mone replacement therapy.
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